Cannara Biotech Stock Buy Hold or Sell Recommendation
| LOVE Stock | CAD 0.78 0.08 11.43% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Cannara Biotech is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Cannara Biotech given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Cannara Biotech, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Cannara Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Cannara and provide practical buy, sell, or hold advice based on investors' constraints. Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Cannara |
Execute Cannara Biotech Buy or Sell Advice
The Cannara recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cannara Biotech. Macroaxis does not own or have any residual interests in Cannara Biotech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cannara Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Cannara Biotech Trading Alerts and Improvement Suggestions
| Cannara Biotech is way too risky over 90 days horizon | |
| Cannara Biotech has some characteristics of a very speculative penny stock | |
| Cannara Biotech appears to be risky and price may revert if volatility continues | |
| Cannara Biotech is unlikely to experience financial distress in the next 2 years | |
| About 49.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024 - Yahoo Finance |
Cannara Biotech Returns Distribution Density
The distribution of Cannara Biotech's historical returns is an attempt to chart the uncertainty of Cannara Biotech's future price movements. The chart of the probability distribution of Cannara Biotech daily returns describes the distribution of returns around its average expected value. We use Cannara Biotech price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cannara Biotech returns is essential to provide solid investment advice for Cannara Biotech.
| Mean Return | 0.45 | Value At Risk | -7.69 | Potential Upside | 12.86 | Standard Deviation | 6.28 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cannara Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cannara Biotech Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (2.5M) | (3.4M) | (8.2M) | (8.3M) | (7.5M) | (7.1M) | |
| Investments | (8.6M) | (30.8M) | (15.3M) | (9.5M) | (10.9M) | (11.4M) | |
| Change In Cash | (18.7M) | 388.1K | 4.0M | (7.8M) | (7.0M) | (6.6M) | |
| Net Borrowings | (235.5K) | (562.7K) | 10.1M | 27.6M | 31.7M | 33.3M | |
| Free Cash Flow | (18.1M) | (33.2M) | (21.5M) | (4.4M) | (5.1M) | (5.4M) | |
| Depreciation | 2.4M | 2.9M | 3.9M | 4.9M | 5.7M | 6.0M | |
| Other Non Cash Items | 1.1M | (169.2K) | (659.0K) | (2.2M) | (2.0M) | (1.9M) | |
| Capital Expenditures | 9.2M | 30.6M | 15.1M | 9.9M | 8.9M | 15.4M | |
| Net Income | (12.5M) | (1.5M) | 2.3M | 6.9M | 8.0M | 8.4M | |
| End Period Cash Flow | 7.8M | 8.2M | 12.1M | 4.3M | 3.8M | 3.7M | |
| Change To Netincome | 4.1M | 1.7M | 189.3K | (937.6K) | (843.9K) | (801.7K) |
Cannara Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cannara Biotech or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cannara Biotech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cannara stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.44 | |
β | Beta against Dow Jones | -0.0053 | |
σ | Overall volatility | 6.38 | |
Ir | Information ratio | 0.07 |
Cannara Biotech Volatility Alert
Cannara Biotech is displaying above-average volatility over the selected time horizon. Cannara Biotech is a potential penny stock. Although Cannara Biotech may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Cannara Biotech. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Cannara instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Cannara Biotech Fundamentals Vs Peers
Comparing Cannara Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cannara Biotech's direct or indirect competition across all of the common fundamentals between Cannara Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cannara Biotech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cannara Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Cannara Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cannara Biotech to competition |
| Fundamentals | Cannara Biotech | Peer Average |
| Return On Equity | 0.0678 | -0.31 |
| Return On Asset | 0.0378 | -0.14 |
| Profit Margin | 0.07 % | (1.27) % |
| Operating Margin | 0.08 % | (5.51) % |
| Current Valuation | 111.92 M | 16.62 B |
| Shares Outstanding | 90.02 M | 571.82 M |
| Shares Owned By Insiders | 49.42 % | 10.09 % |
| Number Of Shares Shorted | 10 | 4.71 M |
| Price To Book | 0.80 X | 9.51 X |
| Price To Sales | 0.92 X | 11.42 X |
| Revenue | 57.26 M | 9.43 B |
| Gross Profit | 17.33 M | 27.38 B |
| EBITDA | 14.29 M | 3.9 B |
| Net Income | 6.95 M | 570.98 M |
| Cash And Equivalents | 5.56 M | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 5.97 M | 5.32 B |
| Debt To Equity | 0.45 % | 48.70 % |
| Current Ratio | 2.95 X | 2.16 X |
| Book Value Per Share | 0.91 X | 1.93 K |
| Cash Flow From Operations | 5.44 M | 971.22 M |
| Short Ratio | 0.03 X | 4.00 X |
| Earnings Per Share | 0.07 X | 3.12 X |
| Beta | 1.07 | -0.15 |
| Market Capitalization | 70.21 M | 19.03 B |
| Total Asset | 141.52 M | 29.47 B |
| Retained Earnings | (19.34 M) | 9.33 B |
| Working Capital | 30.51 M | 1.48 B |
| Net Asset | 141.52 M |
Cannara Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cannara . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cannara Biotech Buy or Sell Advice
When is the right time to buy or sell Cannara Biotech? Buying financial instruments such as Cannara Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cannara Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Soft Drinks Thematic Idea Now
Soft Drinks
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.